在评估过程中，我发现因为没有现成的数据可以进行比较，许多投资者并不了解制药企业在这方面所做的工作。
During our Review, I learned that many in the investment community were not interested in pharmaceutical companies’ behavior on this issue, because there were no readily available data by which to make comparisons.